AUTHORS
Staci Arnold Arnold, MD. MBA, MPH, Zhulin He, PhD2, Tom Michniacki, MD3, Annabel Cincotta, BA4, Elizabeth Korn, BS5, Karyn Brundige, MSN6, Sarah Steltz, MPH7, Leah Cheng, MA, CCRP8, Peter Newburger, MD9, Akiko Shimamura, MD PhD10, Kasiani C. Myers I, MD11
AFFILIATIONS
1 Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta, Emory University, Atlanta, United States
2 Emory University School of Medicine, Atlanta, United States
3 C. S. Mott Children's Hospital, Michigan Medicine, Ann Arbor, United States
4 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States
5 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States
6 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States
7 Boston Children's Hospital, Boston, United States
8 Boston Children's Hospital, Boston, United States
9 University of Massachusetts Chan Medical School, Worcester, United States
10 Boston Children's Hospital, Boston, United States
11 Cincinnati Children's Hospital Medical Center, Cincinnati, United States
ABSTRACT
Introduction: Severe congenital neutropenia is an inherited condition associated with risk of severe, life threatening infections and progression to myelodysplastic syndrome. In those with a suitable donor hematopoietic cell transplant (HCT) is curative but not always necessary. Many patients receive daily injections of granulocyte colony stimulating factor (GCSF) to reduce the infection risk. Although the impact of HCT on patient reported outcomes (PROs) has been reported; the impact of both treatments has not been well studied in this population.
Methods: We recruited participants enrolled in the Severe Congenital Neutropenia International Registry (SCNIR) and the Schwachman Diamond Syndrome (SDS) registry. Each registry captures baseline and longitudinal demographic and treatment-related data. Enrolled participants completed age-appropriate Patient Reported Outcome Measurement Information System (PROMIS) measures. Surveys were sent to participants age 8 years and greater as well as caregivers for participants age 5-18years from May 2025 to January 2026. Participants requiring non-English surveys and adult participants with cognitive impairment were excluded. Standardized T-scores were calculated from raw scores per PROMIS scoring metrics. Subgroup analysis of scores was performed based on age at survey response. Subgroup results were descriptive and, given small strata, hypothesis-generating. Participants also completed a modified Pediatric Quality of Life (PedsQL) survey to further assess the impact of treatment interventions.
Results: Complete PROMIS measures were scored from 224 adults and 50 children with congenital neutropenia. 173 received GCSF therapy and 16 had undergone HCT of whom 5 had graft versus host disease. Mean and median participant PRO scores were in normal ranges according to domain-based assessment of T- scores. Adult scores nearest the “mild” symptom range were depression (mean T- score 49.6 SD 8.9) and fatigue (mean 52.9 SD 10.4). Similarly, children reported fatigue (mean 52.4 SD 10.1) and mobility (mean 46.2 SD 9.9) with scores nearing the “mild” symptom range. While caregiver proxy scores were in the mild range for mobility impairment (mean T-score 43.7 SD 9.2). When PRO scores were analyzed by age at survey response, all scores were normal except caregiver proxy scores for anxiety (age 1-5 mean 57 SD 11.6) and peer relationships (age 12-17 mean 40.8 SD 10.7). Several scores neared the mild range including pediatric mobility (age 6-11 mean 47.2 SD 9.0; age 12-17 mean 45.1 SD 10.9), fatigue (age 12-17 mean 54.3 SD 10.0), peer relationships (age 12-17 mean 46.1 SD 10.2) and caregiver proxy scores for mobility (age 1-5 mean 42.2 SD 6.7 and age 12-17 mean 42.9 SD 9.3), anxiety (age 12-17 mean 53.4 SD 13.9), and peer relationships (age 1-5 mean 46.2 SD 10.5 and age 6-11 mean 45.8 SD12.7). Adult HCT recipients (N=6) had physical function scores nearing the “mild” range (mean 48 SD 10.2) and mild to moderate anxiety (mean 60.2 SD 7.6); pediatric HCT recipients (N=7) had pain interference scores nearing the “mild” range (mean 55.8 SD 8.6). Scores of both pediatric HCT patients and caregiver proxy (N=10) showed moderate impairment in peer relationships (mean 37.6 SD 7.6 and mean 36.6 SD 13.4, respectively). Caregiver proxies for pediatric HCT patients also reported mild fatigue (mean 57.8 SD 11.7). Regarding GCSF treatment, PRO scores were normal, and PEDsQL responses characterized usage as disruptive (79%), bothersome (21%), or associated with bone pain (51%).
Conclusions: This comprehensive analysis of PROs in congenital neutropenia showed, surprisingly, largely normal scores including those receiving GCSF treatment. However, subgroup analysis showed older age and HCT had a negative impact on pediatric peer relationships. Subgroup analysis also showed more anxiety as reported by caregivers of participants age 1-5 years and adults receiving HCT. These findings as well as trends toward mild PRO impairment support further longitudinal study. In addition, these findings highlight potential opportunities for interventional studies targeting these groups.
DISCLOSURES
Staci Arnold Arnold, MD. MBA, MPH: No relevant conflicts of interest to declare.